Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TELA 
Tela Bio Inc (TELA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TELA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.4
1 Year Target Price $5.4
| 3 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.15% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 60.61M USD | Price to earnings Ratio - | 1Y Target Price 5.4 |
Price to earnings Ratio - | 1Y Target Price 5.4 | ||
Volume (30-day avg) 5 | Beta 0.91 | 52 Weeks Range 0.86 - 3.26 | Updated Date 10/17/2025 |
52 Weeks Range 0.86 - 3.26 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -54.12% | Operating Margin (TTM) -44.96% |
Management Effectiveness
Return on Assets (TTM) -36.47% | Return on Equity (TTM) -676.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 66745824 | Price to Sales(TTM) 0.8 |
Enterprise Value 66745824 | Price to Sales(TTM) 0.8 | ||
Enterprise Value to Revenue 0.89 | Enterprise Value to EBITDA -5.01 | Shares Outstanding 39616440 | Shares Floating 18416098 |
Shares Outstanding 39616440 | Shares Floating 18416098 | ||
Percent Insiders 9.01 | Percent Institutions 69.47 |
Upturn AI SWOT
Tela Bio Inc
Company Overview
History and Background
Tela Bio, Inc. was founded in 2012 and is focused on developing and marketing regenerative tissue technologies to address unmet clinical needs in soft tissue reconstruction. They have grown through product development and commercial expansion.
Core Business Areas
- Surgical Reconstruction: Develops and markets biologic scaffolds for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.
- Soft Tissue Reconstruction: Focuses on providing innovative solutions for complex soft tissue procedures using their OviTex Reinforced Tissue Matrix (OviTex) and other advanced materials.
Leadership and Structure
Antony Koblish is President and CEO. The company has a standard corporate structure with departments for R&D, sales, marketing, finance, and operations. Key members of the leadership team include Chris Jablonski (CFO) and Mark Lowney (Chief Commercial Officer).
Top Products and Market Share
Key Offerings
- OviTex Reinforced Tissue Matrix (OviTex): A reinforced tissue matrix made from ovine rumen, primarily used for hernia repair and abdominal wall reconstruction. Competitors include BD (Bard), Ethicon (J&J), and Medtronic. While specific market share data is difficult to obtain, OviTex is a significant player in the biologic mesh market. Revenue from OviTex constitutes a substantial portion of Tela Bio's overall revenue.
- Revolve: Revolve is a novel suturable mesh designed for soft tissue support during plastic and reconstructive surgery. Competitors include BD (Bard), Ethicon (J&J), and Integra LifeSciences. Market share is still being developed for Revolve.
- Epiflex: Epiflex is the newest product and is also for soft tissue support, it has limited data at the moment.
Market Dynamics
Industry Overview
The market for soft tissue reconstruction and regenerative medicine is growing, driven by an aging population, increasing demand for minimally invasive procedures, and advancements in biomaterials. The hernia repair market is a significant segment.
Positioning
Tela Bio is positioned as an innovator in biologic scaffolds, focusing on providing surgeons with durable and cost-effective solutions for complex soft tissue repair. Their competitive advantage lies in their proprietary OviTex technology and focus on outcomes-based data.
Total Addressable Market (TAM)
The total addressable market for soft tissue reconstruction is estimated to be in the billions of dollars. Tela Bio is targeting a significant portion of this TAM through its OviTex and Revolve product lines. They are striving to gain market share from established players.
Upturn SWOT Analysis
Strengths
- Proprietary OviTex technology
- Focus on clinical outcomes
- Experienced management team
- Growing sales force
- Innovative product pipeline
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on key products
- Relatively small market share
- Dependence on reimbursement approvals
- Limited Manufacturing capacity
Opportunities
- Expanding product portfolio
- Gaining market share in existing markets
- Entering new geographic markets
- Acquiring complementary technologies
- Strategic partnerships with larger companies
Threats
- Competition from larger companies with greater resources
- Pricing pressures
- Changes in reimbursement policies
- Regulatory hurdles
- Product liability claims
Competitors and Market Share
Key Competitors
- BD (BDX)
- Ethicon (JNJ)
- Medtronic (MDT)
- Integra LifeSciences (IART)
Competitive Landscape
Tela Bio faces intense competition from larger, more established players. Their success depends on continued innovation, effective marketing, and securing favorable reimbursement.
Growth Trajectory and Initiatives
Historical Growth: Tela Bio has demonstrated growth through increased sales of its OviTex product line. However, this growth has come at the cost of profitability.
Future Projections: Analysts project continued revenue growth for Tela Bio, driven by increased adoption of OviTex and Revolve. Profitability is expected to improve, but timelines are uncertain.
Recent Initiatives: Recent initiatives include expanding the sales force, launching new products (e.g., Revolve, Epiflex), and conducting clinical studies to support product claims.
Summary
Tela Bio is a promising company in the soft tissue reconstruction market with innovative products. However, they face challenges in terms of competition, profitability, and securing sufficient capital. They are growing revenue but must show improved financials. Investors should closely watch their progress toward profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Tela Bio Inc. SEC Filings (10K, 10Q), Company Website, Investor Presentations, Industry Reports, Analyst Estimates.
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tela Bio Inc
Exchange NASDAQ | Headquaters Malvern, PA, United States | ||
IPO Launch date 2019-11-08 | Co-founder, CEO & Director Mr. Antony Koblish | ||
Sector Healthcare | Industry Medical Devices | Full time employees 209 | Website https://www.telabio.com |
Full time employees 209 | Website https://www.telabio.com | ||
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.